Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide for Prevention of Toxicity in High-dose Chemotherapy with Autologous HSCT
2022-502139-20-00Phase 2Authorised
- Sponsor
- Rigshospitalet
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in mucositis and chronic inflammation comparing Semaglutide with Placebo (2 arms). Primary endpoint: Gastrointestinal mucositis severity. Planned start Mar 2023; status: authorised.
02
Drugs
03
Conditions
mucositischronic inflammation
Beyond the preview
Go deeper on 2022-502139-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502139-20-00.